---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-077264"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2022-03-16T23:59:59+00:00"
generated_at: "2026-06-26T22:24:27.256587+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics CFO Steve Krognes to join Board; COO Alex Schuth adds CFO role effective May 1, 2022

## Summary
- Krognes transitions from CFO to Class III director as of May 1, 2022; his term expires at 2023 annual meeting.
- Alexander Schuth, current COO and Secretary, becomes Chief Operating and Financial Officer on May 1, 2022.
- No changes to Schuth's compensation in connection with his expanded role; Krognes to receive standard board cash and equity.
- Krognes cited a personal desire to move back to Europe; Watts and Board expressed gratitude and support for continuity.

## SEC filing metadata
- accession: 0001193125-22-077264
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2022-03-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/d310285d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-077264
- JSON: https://secwatch.observer/filing/0001193125-22-077264.json
- Plain text: https://secwatch.observer/filing/0001193125-22-077264.txt

## Key facts
- Executive change
  Alexander Schuth was appointed as Chief Operating and Financial Officer at Denali Therapeutics Inc..
  - Action: appointed
  - Role: Chief Operating and Financial Officer
  source text: Alexander Schuth, M.D., current Chief Operating Officer and Secretary of the Company, will add the Chief Financial Officer role to his current responsibilities, becoming Denali’s Chief Operating and Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm
- Executive change
  Steve Krognes changed role as Chief Financial Officer at Denali Therapeutics Inc..
  - Action: transitioned
  - Role: Chief Financial Officer
  source text: Steve Krognes will transition from his role as Chief Financial Officer to join the Company’s Board of Directors as of May 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm
- Executive change
  Steve Krognes was appointed as Director at Denali Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On March 14, 2022, Mr. Krognes was appointed to the Board, effective May 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.